Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
31
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Siren, L.L.C. | 10% Owner | 7 | $0 | $447.7K | 2024-08-08 |
| Invus Public Equities Advisors, LLC | 10% Owner | 2 | $0 | $41.3K | 2024-08-06 |
| Rock Edwin | Chief Medical Officer | 10 | $725.3K | $0 | 2024-06-21 |
| Hahn Brian M. | SVP Finance, CFO | 24 | $25.6K | $359.4K | 2024-06-18 |
| King Rachel K. | President, CEO | 24 | $0 | $329.1K | 2024-05-01 |
| Koenig Scott | Director | 14 | $0 | $0 | 2024-05-01 |
| Jackson Scott Thomas | Director | 8 | $0 | $0 | 2024-05-01 |
| Goldberg Mark Alan | Director | 16 | $49.6K | $0 | 2024-05-01 |
| PEARSON TIMOTHY R | Director | 14 | $25.0K | $0 | 2024-05-01 |
| Andrews Patricia S | Director | 12 | $82.0K | $0 | 2024-05-01 |
| JUNIUS DANIEL M | Director | 18 | $214.1K | $0 | 2024-05-01 |
| Johnson Bruce S | SVP & Chief Commercial Officer | 2 | $21.2K | $0 | 2024-01-12 |
| Rath Chinmaya | SVP and Chief Business Officer | 1 | $0 | $0 | 2024-01-12 |
| Semerjian Harout | Chief Executive Officer | 4 | $32.3K | $0 | 2024-01-12 |
| Wittouck Amaury | 10% Owner | 5 | $3.24M | $0 | 2023-02-24 |
| Artal Group S.A. | 10% Owner | 3 | $711.0K | $0 | 2023-02-23 |
| SANDELL SCOTT D | 10% Owner | 27 | $8.00M | $13.04M | 2023-01-26 |
| Girard Armand | SVP, Chief Business Officer | 7 | $6.8K | $2.5K | 2022-11-11 |
| Magnani John L. | VP of Research, CSO | 27 | $52.7K | $353.7K | 2022-11-11 |
| Thackray Helen M. | VP Clinical Development, CMO | 19 | $0 | $309.4K | 2021-01-20 |
| BVF INC/IL | 10% Owner | 6 | $5.86M | $0 | 2020-11-04 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 3 | $5.31M | $0 | 2019-09-05 |
| BARRETT M JAMES | Director, 10% Owner | 20 | $8.00M | $173.0K | 2018-05-18 |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | 9 | $0 | $173.0K | 2018-05-10 |
| BARRIS PETER J | 10% Owner | 15 | $8.00M | $173.0K | 2018-05-10 |
| Baldwin John J. | Director | 5 | $0 | $0 | 2016-06-29 |
| TOP FRANKLIN H JR | Director | 6 | $0 | $0 | 2016-05-17 |
| HENOS MICHAEL A | Director | 17 | $70.3K | $241.6K | 2015-07-15 |
| Gust William M. | Director | 3 | $0 | $0 | 2014-01-15 |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | 3 | $4.10M | $0 | 2014-01-15 |
| NEA PARTNERS 10 L P | 10% Owner | 3 | $3.90M | $0 | 2014-01-15 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Siren, L.L.C. | 10% Owner | S Sale | 2024-08-08 | 2024-08-09 | 260,873 | $0.19 | $49.6K | 6,317,565 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-08-07 | 2024-08-09 | 61,488 | $0.18 | $11.1K | 6,578,438 | SEC↗ |
| Invus Public Equities Advisors | 10% Owner | S Sale | 2024-08-06 | 2024-08-07 | 55,732 | $0.18 | $10.0K | 6,639,926 | SEC↗ |
| Invus Public Equities Advisors | 10% Owner | S Sale | 2024-08-05 | 2024-08-07 | 164,523 | $0.19 | $31.3K | 6,695,658 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-08-02 | 2024-08-05 | 286,200 | $0.20 | $57.2K | 6,860,181 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-08-01 | 2024-08-05 | 63,564 | $0.22 | $14.0K | 7,146,381 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-07-30 | 2024-07-30 | 756,835 | $0.22 | $166.5K | 7,209,945 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-07-29 | 2024-07-30 | 363,949 | $0.24 | $87.3K | 7,966,780 | SEC↗ |
| Siren, L.L.C. | 10% Owner | S Sale | 2024-07-26 | 2024-07-30 | 258,335 | $0.24 | $62.0K | 8,330,729 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2024-06-21 | 2024-06-24 | 115,000 | $0.27 | $31.1K | 680,403 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2024-06-20 | 2024-06-24 | 190,000 | $0.25 | $47.5K | 565,403 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | P Buy | 2024-06-18 | 2024-06-20 | 17,500 | $0.25 | $4.4K | 70,643 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2024-05-01 | 2024-05-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| King Rachel K. | Director | A Award | 2024-03-29 | 2024-04-02 | 3,334 | $3.00 | $10.0K | 515,194 | SEC↗ |
| Goldberg Mark Alan | Director | A Award | 2024-03-29 | 2024-04-02 | 4,584 | $3.00 | $13.8K | 24,828 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award | 2024-03-29 | 2024-04-02 | 5,209 | $3.00 | $15.6K | 98,459 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2024-01-12 | 2024-01-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Rath Chinmaya | SVP and Chief Business Offic | A Award deriv | 2024-01-12 | 2024-01-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Rock Edwin | Chief Medical Officer | A Award deriv | 2024-01-12 | 2024-01-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Semerjian Harout | Chief Executive Officer | A Award deriv | 2024-01-12 | 2024-01-17 | 695,000 | — | $0 | 695,000 | SEC↗ |
| Johnson Bruce S | SVP & Chief Commercial Offic | A Award deriv | 2024-01-12 | 2024-01-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award | 2023-12-29 | 2024-01-02 | 5,827 | $2.36 | $13.8K | 20,244 | SEC↗ |
| King Rachel K. | Director | A Award | 2023-12-29 | 2024-01-02 | 4,238 | $2.36 | $10.0K | 511,860 | SEC↗ |
| Andrews Patricia S | Director | A Award | 2023-12-29 | 2024-01-02 | 5,191 | $2.36 | $12.3K | 58,608 | SEC↗ |
| King Rachel K. | Director | A Award | 2023-09-30 | 2023-10-03 | 6,667 | $1.50 | $10.0K | 507,622 | SEC↗ |
| Andrews Patricia S | Director | A Award | 2023-09-30 | 2023-10-03 | 8,167 | $1.50 | $12.3K | 53,417 | SEC↗ |
| Goldberg Mark Alan | Director | A Award | 2023-09-30 | 2023-10-03 | 9,167 | $1.50 | $13.8K | 14,417 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2023-09-22 | 2023-09-25 | 30,403 | $1.38 | $42.0K | 375,403 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2023-09-21 | 2023-09-25 | 35,000 | $1.38 | $48.3K | 345,000 | SEC↗ |
| Koenig Scott | Director | M Exercise deriv | 2023-06-01 | 2023-06-02 | 21,000 | — | $0 | 0 | SEC↗ |
| Koenig Scott | Director | M Exercise | 2023-06-01 | 2023-06-02 | 21,000 | $0.60 | $12.6K | 36,750 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2023-05-19 | 2023-05-22 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | S Sale | 2023-05-17 | 2023-05-18 | 3,700 | $1.95 | $7.2K | 53,143 | SEC↗ |
| JUNIUS DANIEL M | Director | P Buy | 2023-05-10 | 2023-05-11 | 30,000 | $1.56 | $46.8K | 93,250 | SEC↗ |
| Johnson Bruce S | SVP & Chief Commercial Offic | P Buy | 2023-05-08 | 2023-05-09 | 13,500 | $1.57 | $21.2K | 138,980 | SEC↗ |
| Wittouck Amaury | 10% Owner | P Buy | 2023-02-24 | 2023-02-28 | 100,000 | $1.70 | $170.0K | 8,589,064 | SEC↗ |
| Artal Group S.A. | 10% Owner | P Buy | 2023-02-23 | 2023-02-23 | 200,000 | $1.75 | $350.0K | 8,489,064 | SEC↗ |
| Artal Group S.A. | 10% Owner | P Buy | 2023-02-22 | 2023-02-23 | 150,000 | $1.79 | $268.5K | 8,289,064 | SEC↗ |
| Artal Group S.A. | 10% Owner | P Buy | 2023-02-21 | 2023-02-23 | 50,000 | $1.85 | $92.5K | 8,139,064 | SEC↗ |
| Wittouck Amaury | 10% Owner | P Buy | 2023-02-17 | 2023-02-17 | 200,000 | $1.71 | $342.0K | 8,089,064 | SEC↗ |
| Wittouck Amaury | 10% Owner | P Buy | 2023-02-16 | 2023-02-17 | 315,266 | $1.68 | $529.6K | 7,889,064 | SEC↗ |
| Wittouck Amaury | 10% Owner | P Buy | 2023-02-15 | 2023-02-17 | 1,000,000 | $2.16 | $2.16M | 7,573,798 | SEC↗ |
| Wittouck Amaury | 10% Owner | P Buy | 2023-02-09 | 2023-02-13 | 11,451 | $3.24 | $37.1K | 6,573,798 | SEC↗ |
| Koenig Scott | Director | M Exercise deriv | 2023-01-27 | 2023-01-30 | 10,500 | — | $0 | 0 | SEC↗ |
| Koenig Scott | Director | M Exercise | 2023-01-27 | 2023-01-30 | 10,500 | $2.55 | $26.8K | 15,750 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-26 | 2023-01-27 | 1,351,092 | $3.12 | $4.22M | 2,237,196 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-26 | 2023-01-27 | 1,648,908 | $3.12 | $5.14M | 2,730,334 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-25 | 2023-01-27 | 358,371 | $3.26 | $1.17M | 4,379,242 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-25 | 2023-01-27 | 293,645 | $3.26 | $957.3K | 3,588,288 | SEC↗ |
| Rock Edwin | Chief Medical Officer | A Award deriv | 2023-01-19 | 2023-01-20 | 244,800 | — | $0 | 244,800 | SEC↗ |
| Semerjian Harout | Chief Executive Officer | A Award deriv | 2023-01-19 | 2023-01-20 | 651,200 | — | $0 | 651,200 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2023-01-19 | 2023-01-20 | 246,300 | — | $0 | 246,300 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-05 | 2023-01-06 | 32,139 | $2.76 | $88.7K | 3,881,933 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-05 | 2023-01-06 | 39,223 | $2.76 | $108.3K | 4,737,613 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-04 | 2023-01-04 | 56,054 | $2.91 | $163.1K | 4,776,836 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-04 | 2023-01-04 | 45,930 | $2.91 | $133.7K | 3,914,072 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-03 | 2023-01-04 | 78,730 | $2.99 | $235.4K | 3,960,002 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2023-01-03 | 2023-01-04 | 96,084 | $2.99 | $287.3K | 4,832,890 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2022-12-30 | 2023-01-04 | 66,690 | $3.02 | $201.4K | 4,928,974 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2022-12-30 | 2023-01-04 | 54,645 | $3.02 | $165.0K | 4,038,732 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2022-12-22 | 2022-12-27 | 110,000 | $2.25 | $247.5K | 310,000 | SEC↗ |
| JUNIUS DANIEL M | Director | P Buy | 2022-11-17 | 2022-11-18 | 20,000 | $1.87 | $37.4K | 63,250 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2022-11-15 | 2022-11-16 | 100,000 | $1.66 | $166.0K | 200,000 | SEC↗ |
| Rock Edwin | Chief Medical Officer | P Buy | 2022-11-14 | 2022-11-16 | 100,000 | $1.43 | $143.0K | 100,000 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | P Buy | 2022-11-11 | 2022-11-14 | 6,500 | $1.05 | $6.8K | 29,161 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | P Buy | 2022-11-11 | 2022-11-14 | 45,045 | $1.17 | $52.7K | 366,078 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | P Buy | 2022-11-11 | 2022-11-14 | 20,000 | $1.06 | $21.2K | 56,843 | SEC↗ |
| Semerjian Harout | Chief Executive Officer | P Buy | 2022-11-11 | 2022-11-14 | 25,000 | $1.29 | $32.3K | 25,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | P Buy | 2022-11-11 | 2022-11-14 | 19,400 | $1.29 | $25.0K | 24,650 | SEC↗ |
| Rock Edwin | Chief Medical Officer | A Award deriv | 2022-09-02 | 2022-09-07 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2022-05-18 | 2022-05-20 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | S Sale | 2022-03-09 | 2022-03-10 | 2,917 | $1.09 | $3.2K | 36,843 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | S Sale | 2022-03-09 | 2022-03-10 | 2,339 | $1.09 | $2.5K | 22,661 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | S Sale | 2022-03-09 | 2022-03-10 | 3,227 | $1.09 | $3.5K | 321,033 | SEC↗ |
| Semerjian Harout | Chief Executive Officer | A Award deriv | 2022-01-21 | 2022-01-25 | 423,500 | — | $0 | 423,500 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2022-01-21 | 2022-01-25 | 47,700 | — | $0 | 47,700 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2022-01-21 | 2022-01-25 | 164,700 | — | $0 | 164,700 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2022-01-21 | 2022-01-25 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2022-01-21 | 2022-01-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | A Award deriv | 2022-01-21 | 2022-01-25 | 144,700 | — | $0 | 144,700 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | A Award deriv | 2022-01-21 | 2022-01-25 | 47,700 | — | $0 | 47,700 | SEC↗ |
| Andrews Patricia S | Director | P Buy | 2021-11-16 | 2021-11-18 | 40,000 | $2.05 | $82.0K | 45,250 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2021-05-18 | 2021-05-27 | 10,500 | — | $0 | 10,500 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 5,250 | SEC↗ |
| Koenig Scott | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 5,250 | SEC↗ |
| Goldberg Mark Alan | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 5,250 | SEC↗ |
| Andrews Patricia S | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 5,250 | SEC↗ |
| Jackson Scott Thomas | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 5,250 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award | 2021-05-18 | 2021-05-27 | 5,250 | — | $0 | 43,250 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2021-01-20 | 2021-01-22 | 192,500 | — | $0 | 192,500 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2021-01-20 | 2021-01-22 | 69,000 | — | $0 | 69,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award deriv | 2021-01-20 | 2021-01-22 | 69,000 | — | $0 | 69,000 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2021-01-20 | 2021-01-22 | 69,000 | — | $0 | 69,000 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | A Award deriv | 2021-01-20 | 2021-01-22 | 50,000 | — | $0 | 50,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award | 2021-01-20 | 2021-01-22 | 96,250 | — | $0 | 452,314 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award | 2021-01-20 | 2021-01-22 | 34,500 | — | $0 | 324,260 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award | 2021-01-20 | 2021-01-22 | 34,500 | — | $0 | 183,115 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award | 2021-01-20 | 2021-01-22 | 34,500 | — | $0 | 39,760 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | A Award | 2021-01-20 | 2021-01-22 | 25,000 | — | $0 | 25,000 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise deriv | 2020-12-28 | 2020-12-30 | 130,821 | — | $0 | 0 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise | 2020-12-28 | 2020-12-30 | 130,821 | $1.12 | $146.5K | 440,240 | SEC↗ |
| King Rachel K. | President, CEO | S Sale | 2020-12-28 | 2020-12-30 | 84,176 | $3.91 | $329.1K | 356,064 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | M Exercise deriv | 2020-12-16 | 2020-12-17 | 5,260 | — | $0 | 0 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | M Exercise | 2020-12-16 | 2020-12-17 | 5,260 | $1.12 | $5.9K | 5,260 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-11-04 | 2020-11-06 | 674,492 | $2.60 | $1.75M | 4,980,812 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-11-04 | 2020-11-06 | 86,090 | $2.60 | $223.8K | 630,453 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-11-04 | 2020-11-06 | 506,155 | $2.60 | $1.32M | 3,712,350 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-10-30 | 2020-11-03 | 666,385 | $2.75 | $1.83M | 4,306,320 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-10-30 | 2020-11-03 | 250,755 | $2.75 | $689.6K | 3,206,195 | SEC↗ |
| BVF INC/IL | 10% Owner | P Buy | 2020-10-30 | 2020-11-03 | 15,472 | $2.75 | $42.5K | 544,363 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2020-05-22 | 2020-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| JUNIUS DANIEL M | Director | P Buy | 2020-03-09 | 2020-03-10 | 20,000 | $3.40 | $68.0K | 38,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2020-01-22 | 2020-01-24 | 349,000 | — | $0 | 349,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award deriv | 2020-01-22 | 2020-01-24 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2020-01-22 | 2020-01-24 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2020-01-22 | 2020-01-24 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Girard Armand | SVP, Chief Business Officer | A Award deriv | 2020-01-22 | 2020-01-24 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise deriv | 2020-01-06 | 2020-01-06 | 106,983 | — | $0 | 0 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise | 2020-01-06 | 2020-01-06 | 106,983 | $1.12 | $119.8K | 289,760 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise deriv | 2019-12-20 | 2019-12-23 | 106,984 | — | $0 | 106,983 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise | 2019-12-20 | 2019-12-23 | 106,984 | $1.12 | $119.8K | 182,777 | SEC↗ |
| BIOTECHNOLOGY VALUE FUND II LP | Other | P Buy | 2019-09-05 | 2019-09-09 | 689,834 | $3.18 | $2.19M | 2,955,440 | SEC↗ |
| BIOTECHNOLOGY VALUE FUND II LP | Other | P Buy | 2019-09-05 | 2019-09-09 | 124,956 | $3.18 | $397.4K | 528,891 | SEC↗ |
| BIOTECHNOLOGY VALUE FUND II LP | Other | P Buy | 2019-09-05 | 2019-09-09 | 853,956 | $3.18 | $2.72M | 3,639,935 | SEC↗ |
| JUNIUS DANIEL M | Director | P Buy | 2019-08-13 | 2019-08-15 | 10,000 | $3.18 | $31.8K | 18,000 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise deriv | 2019-08-06 | 2019-08-07 | 166,759 | — | $0 | 130,821 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise | 2019-08-06 | 2019-08-07 | 166,759 | $1.12 | $186.8K | 307,144 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2019-05-17 | 2019-05-21 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Hahn Brian M. | SVP Finance, CFO | A Award deriv | 2019-01-17 | 2019-01-22 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award deriv | 2019-01-17 | 2019-01-22 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2019-01-17 | 2019-01-22 | 100,000 | — | $0 | 100,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2019-01-17 | 2019-01-22 | 265,000 | — | $0 | 265,000 | SEC↗ |
| Jackson Scott Thomas | Director | A Award deriv | 2018-11-27 | 2018-11-28 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | S Sale | 2018-10-18 | 2018-10-18 | 3,527 | $14.02 | $49.4K | 75,793 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | S Sale | 2018-10-17 | 2018-10-18 | 7,273 | $14.00 | $101.8K | 79,320 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | S Sale | 2018-10-16 | 2018-10-18 | 14,200 | $14.01 | $198.9K | 86,593 | SEC↗ |
| Hahn Brian M. | CFO | M Exercise deriv | 2018-06-11 | 2018-06-12 | 5,260 | — | $0 | 5,260 | SEC↗ |
| Hahn Brian M. | CFO | M Exercise | 2018-06-11 | 2018-06-12 | 5,260 | $1.12 | $5.9K | 19,345 | SEC↗ |
| Hahn Brian M. | CFO | S Sale | 2018-06-11 | 2018-06-12 | 19,345 | $18.04 | $349.0K | 0 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise deriv | 2018-05-23 | 2018-05-24 | 596 | — | $0 | 0 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise deriv | 2018-05-23 | 2018-05-24 | 895 | — | $0 | 0 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise | 2018-05-23 | 2018-05-24 | 1,491 | $0.33 | $492 | 100,793 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | A Award deriv | 2018-05-18 | 2018-05-21 | 11,000 | — | $0 | 11,000 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 216,046 | — | $0 | 0 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 298,406 | — | $0 | 0 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 298,406 | — | $0 | 0 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 216,046 | — | $0 | 0 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 216,046 | — | $0 | 0 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 298,406 | — | $0 | 0 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 298,406 | — | $0 | 0 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise deriv | 2018-05-10 | 2018-05-11 | 216,046 | — | $0 | 0 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 298,406 | $0.33 | $98.5K | 5,001,197 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 4,006 | $17.81 | $71.3K | 4,702,791 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 216,046 | $0.33 | $71.3K | 4,706,797 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 5,533 | $17.81 | $98.5K | 4,995,664 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 298,406 | $0.33 | $98.5K | 5,001,197 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 4,006 | $17.81 | $71.3K | 4,702,791 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 216,046 | $0.33 | $71.3K | 4,706,797 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 5,533 | $17.81 | $98.5K | 4,995,664 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 216,046 | $0.33 | $71.3K | 4,706,797 | SEC↗ |
| BARRIS PETER J | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 5,533 | $17.81 | $98.5K | 4,995,664 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 298,406 | $0.33 | $98.5K | 5,001,197 | SEC↗ |
| BARRIS PETER J | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 4,006 | $17.81 | $71.3K | 4,702,791 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 5,533 | $17.81 | $98.5K | 4,995,664 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 216,046 | $0.33 | $71.3K | 4,706,797 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2018-05-10 | 2018-05-11 | 4,006 | $17.81 | $71.3K | 4,702,791 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise | 2018-05-10 | 2018-05-11 | 298,406 | $0.33 | $98.5K | 5,001,197 | SEC↗ |
| Hahn Brian M. | CFO | A Award deriv | 2018-01-10 | 2018-01-12 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2018-01-10 | 2018-01-12 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award deriv | 2018-01-10 | 2018-01-12 | 75,000 | — | $0 | 75,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2018-01-10 | 2018-01-12 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | S Sale | 2017-12-08 | 2017-12-12 | 2,000 | $15.01 | $30.0K | 148,615 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | S Sale | 2017-09-18 | 2017-09-18 | 2,000 | $13.00 | $26.0K | 150,615 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award | 2017-06-15 | 2017-06-16 | 3,000 | $11.27 | $33.8K | 8,000 | SEC↗ |
| Andrews Patricia S | Director | A Award deriv | 2017-06-09 | 2017-06-12 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2017-05-25 | 2017-05-30 | 11,000 | — | $0 | 11,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2017-05-25 | 2017-05-30 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2017-05-25 | 2017-05-30 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2017-05-25 | 2017-05-30 | 11,000 | — | $0 | 11,000 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | A Award deriv | 2017-05-25 | 2017-05-30 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | S Sale | 2017-05-25 | 2017-05-30 | 2,000 | $15.57 | $31.1K | 152,615 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | S Sale | 2017-05-19 | 2017-05-22 | 2,000 | $12.14 | $24.3K | 154,615 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise deriv | 2017-05-10 | 2017-05-11 | 8,928 | — | $0 | 213,967 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | M Exercise | 2017-05-10 | 2017-05-11 | 8,928 | $1.12 | $10.0K | 99,302 | SEC↗ |
| Koenig Scott | Director | A Award deriv | 2017-03-09 | 2017-03-13 | 22,000 | — | $0 | 22,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2017-01-04 | 2017-01-05 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Hahn Brian M. | CFO | A Award deriv | 2017-01-04 | 2017-01-05 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Thackray Helen M. | SVP Clinical Development, CM | A Award deriv | 2017-01-04 | 2017-01-05 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Magnani John L. | SVP of Research, CSO | A Award deriv | 2017-01-04 | 2017-01-05 | 75,000 | — | $0 | 75,000 | SEC↗ |
| JUNIUS DANIEL M | Director | P Buy | 2016-12-20 | 2016-12-21 | 5,000 | $6.01 | $30.1K | 5,000 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-10-03 | 2016-10-04 | 100 | $7.01 | $701 | 156,615 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-10-03 | 2016-10-04 | 3,900 | $7.00 | $27.3K | 156,715 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-07-20 | 2016-07-21 | 2,000 | $8.00 | $16.0K | 160,615 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-07-06 | 2016-07-06 | 6,796 | $6.68 | $45.4K | 162,615 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-07-05 | 2016-07-06 | 10,136 | $7.01 | $71.1K | 169,411 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | S Sale | 2016-07-01 | 2016-07-06 | 5,068 | $7.40 | $37.5K | 179,547 | SEC↗ |
| Baldwin John J. | Director | M Exercise deriv | 2016-06-29 | 2016-07-01 | 605 | — | $0 | 0 | SEC↗ |
| Baldwin John J. | Director | M Exercise | 2016-06-29 | 2016-07-01 | 605 | $1.12 | $678 | 1,210 | SEC↗ |
| Baldwin John J. | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| TOP FRANKLIN H JR | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2016-05-17 | 2016-05-19 | 11,000 | — | $0 | 11,000 | SEC↗ |
| JUNIUS DANIEL M | Director | A Award deriv | 2016-03-17 | 2016-03-21 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Goldberg Mark Alan | Director | P Buy | 2016-03-04 | 2016-03-07 | 10,397 | $4.77 | $49.6K | 11,497 | SEC↗ |
| TOP FRANKLIN H JR | Director | M Exercise deriv | 2016-02-05 | 2016-02-12 | 11,084 | $1.12 | $12.4K | 0 | SEC↗ |
| TOP FRANKLIN H JR | Director | M Exercise deriv | 2016-02-05 | 2016-02-12 | 605 | $1.12 | $678 | 0 | SEC↗ |
| TOP FRANKLIN H JR | Director | M Exercise | 2016-02-05 | 2016-02-12 | 11,689 | $1.12 | $13.1K | 12,294 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | A Award deriv | 2016-01-07 | 2016-01-11 | 71,000 | — | $0 | 71,000 | SEC↗ |
| Magnani John L. | VP of Research, CSO | A Award deriv | 2016-01-07 | 2016-01-11 | 71,000 | — | $0 | 71,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2016-01-07 | 2016-01-11 | 141,000 | — | $0 | 141,000 | SEC↗ |
| Hahn Brian M. | CFO | A Award deriv | 2016-01-07 | 2016-01-11 | 65,000 | — | $0 | 65,000 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise deriv | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 0 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise deriv | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 0 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise deriv | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 0 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise deriv | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 0 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | S Sale | 2015-11-16 | 2015-11-18 | 452 | $6.91 | $3.1K | 4,490,751 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 10 L | 10% Owner | X Exercise | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 4,491,203 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | X Exercise | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 4,491,203 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | S Sale | 2015-11-16 | 2015-11-18 | 452 | $6.91 | $3.1K | 4,490,751 | SEC↗ |
| BARRIS PETER J | 10% Owner | S Sale | 2015-11-16 | 2015-11-18 | 452 | $6.91 | $3.1K | 4,490,751 | SEC↗ |
| BARRIS PETER J | 10% Owner | X Exercise | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 4,491,203 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | S Sale | 2015-11-16 | 2015-11-18 | 452 | $6.91 | $3.1K | 4,490,751 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | X Exercise | 2015-11-16 | 2015-11-18 | 9,445 | $0.33 | $3.1K | 4,491,203 | SEC↗ |
| HENOS MICHAEL A | Director | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| TOP FRANKLIN H JR | Director | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Baldwin John J. | Director | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | A Award deriv | 2015-07-15 | 2015-08-11 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Hahn Brian M. | CFO | M Exercise deriv | 2015-02-27 | 2015-03-03 | 5,000 | — | $0 | 10,520 | SEC↗ |
| Hahn Brian M. | CFO | M Exercise | 2015-02-27 | 2015-03-03 | 5,000 | $1.12 | $5.6K | 14,085 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise deriv | 2015-02-24 | 2015-02-26 | 50,000 | — | $0 | 297,580 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise | 2015-02-24 | 2015-02-26 | 50,000 | $1.12 | $56.0K | 167,206 | SEC↗ |
| Hahn Brian M. | CFO | A Award deriv | 2015-01-08 | 2015-01-12 | 61,000 | — | $0 | 61,000 | SEC↗ |
| King Rachel K. | President, CEO | A Award deriv | 2015-01-08 | 2015-01-12 | 141,000 | — | $0 | 141,000 | SEC↗ |
| Thackray Helen M. | VP Clinical Development, CMO | A Award deriv | 2015-01-08 | 2015-01-12 | 71,000 | — | $0 | 71,000 | SEC↗ |
| Magnani John L. | VP of Research, CSO | A Award deriv | 2015-01-08 | 2015-01-12 | 71,000 | — | $0 | 71,000 | SEC↗ |
| HENOS MICHAEL A | Director | S Sale | 2014-12-22 | 2014-12-23 | 10,659 | $8.44 | $90.0K | 469,454 | SEC↗ |
| HENOS MICHAEL A | Director | S Sale | 2014-12-19 | 2014-12-23 | 10,598 | $8.61 | $91.2K | 480,113 | SEC↗ |
| HENOS MICHAEL A | Director | S Sale | 2014-12-17 | 2014-12-17 | 5,121 | $8.97 | $45.9K | 490,711 | SEC↗ |
| HENOS MICHAEL A | Director | X Exercise deriv | 2014-12-15 | 2014-12-17 | 38,493 | — | $0 | 0 | SEC↗ |
| HENOS MICHAEL A | Director | X Exercise deriv | 2014-12-15 | 2014-12-17 | 5,133 | — | $0 | 0 | SEC↗ |
| HENOS MICHAEL A | Director | X Exercise | 2014-12-15 | 2014-12-17 | 43,628 | $0.33 | $14.4K | 497,436 | SEC↗ |
| HENOS MICHAEL A | Director | S Sale | 2014-12-15 | 2014-12-17 | 1,604 | $8.98 | $14.4K | 495,832 | SEC↗ |
| Goldberg Mark Alan | Director | A Award deriv | 2014-07-08 | 2014-07-10 | 15,401 | — | $0 | 15,401 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise deriv | 2014-06-18 | 2014-06-20 | 100,000 | — | $0 | 347,580 | SEC↗ |
| King Rachel K. | President, CEO | M Exercise | 2014-06-18 | 2014-06-20 | 100,000 | $1.12 | $112.0K | 108,706 | SEC↗ |
| HENOS MICHAEL A | Director | P Buy | 2014-06-13 | 2014-06-13 | 5,000 | $6.21 | $31.1K | 12,562 | SEC↗ |
| HENOS MICHAEL A | Director | P Buy | 2014-06-12 | 2014-06-13 | 6,000 | $6.54 | $39.2K | 7,562 | SEC↗ |
| HENOS MICHAEL A | Director | M Exercise deriv | 2014-04-03 | 2014-04-03 | 1,562 | — | $0 | 0 | SEC↗ |
| HENOS MICHAEL A | Director | M Exercise | 2014-04-03 | 2014-04-03 | 1,562 | $1.12 | $1.7K | 1,562 | SEC↗ |
| PEARSON TIMOTHY R | Director | A Award deriv | 2014-03-31 | 2014-04-01 | 15,401 | — | $0 | 15,401 | SEC↗ |
| Gust William M. | Director | C Conversion deriv | 2014-01-15 | 2014-01-15 | 1,121,646 | — | $0 | 0 | SEC↗ |
| HENOS MICHAEL A | Director | C Conversion deriv | 2014-01-15 | 2014-01-15 | 39,413 | — | $0 | 0 | SEC↗ |
| HENOS MICHAEL A | Director | C Conversion deriv | 2014-01-15 | 2014-01-15 | 1,114,690 | — | $0 | 0 | SEC↗ |
| Magnani John L. | VP of Research, CSO | C Conversion deriv | 2014-01-15 | 2014-01-15 | 32,918 | — | $0 | 0 | SEC↗ |
| NEA PARTNERS 10 L P | 10% Owner | C Conversion deriv | 2014-01-15 | 2014-01-15 | 11,250,850 | — | $0 | 0 | SEC↗ |
| NEW ENTERPRISE ASSOCIATES 13 L | 10% Owner | C Conversion deriv | 2014-01-15 | 2014-01-15 | 11,824,058 | — | $0 | 0 | SEC↗ |
| BARRETT M JAMES | Director, 10% Owner | C Conversion deriv | 2014-01-15 | 2014-01-15 | 11,824,058 | — | $0 | 0 | SEC↗ |